Comparative Pharmacokinetic Study of Mangiferin in Normal and Alloxan-Induced Diabetic Rats after Oral and Intravenous Administration by UPLC-MS/MS
Abstract
Backgrounds Diabetes mellitus (DM)-induced morphological and/or functional complications may alter the pharmacokinetic profiles of mangiferin. This study aims to compare pharmacokinetic profiles of mangiferin in normal and alloxan-induced diabetic rats after oral and intravenous administration. Methods Mangiferin was administered orally (10 mg/kg) and intravenously (2 mg/kg) to normal and alloxan-induced diabetic Sprague-Dawley (SD) rats (n = 8). Blood samples were collected at different time points post-dose. Mangiferin and esculentoside (internal standard) were analyzed by Waters Acquity ultra-performance liquid chromatography system and TSQ Quantum Ultra triple quadrupole mass spectrometer (UPLC-MS/MS). Results Mangiferin in normal and alloxan-induced diabetic rats experienced serious first-pass effect, which resulted in 1.71 and 0.80% of oral bioavailability respectively. Meanwhile, mangiferin was predominantly restricted to blood but not extensively distributed to organ tissues after intravenous administration. Compared with normal rats, the diabetic condition induced 53.26 and 50.90% decreases in Cmax and AUC0-t, respectively, for mangiferin after oral administration, and 63.08% decreases in Cmax after intravenous administration. Conclusions Compared to normal rats, pharmacokinetic parameters of mangiferin were altered in diabetic condition induced by alloxan. The findings might help to provide useful evidence for modeling of diabetic rats and the clinical applications…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Extensive first-pass hepatic metabolism further decreases the amount of active MGF entering systemic circulation.
“Additionally, extensive first-pass hepatic metabolism further decreases the amount of active MGF entering systemic circulation (17).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [17]
Only 1.15% of orally administered MGF (30 mg/kg) is bioavailable in mice, whereas intraperitoneal administration results in markedly increased systemic levels.
“A previous in vivo study demonstrated that only 1.15% of orally administered MGF (30 mg/kg) is bioavailable in mice, whereas intraperitoneal administration results in markedly increased systemic levels.”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [17]
Cited by
Sorted by citations
Recent Formulation Advances of Mangiferin
Barakat, S., Nasr, M., Ahmed, R. F., Badawy, S., & Mortada, N. (2022) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-022-00297-z · Cited by 28 · see citing works
Bunt, D., Schwalbe, M., Hayeeawaema, F., & El Aidy, S. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2508422 · Cited by 10 · see citing works
Mangiferin in human disease: Multifaceted mechanisms and applications (Review)
Dai, Y., Huang, Q., Tan, M., Wang, Z., Jiang, C., Liu, Z., Zhang, S., & Song, S. (2026) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2026.5736 · Cited by 3 · see citing works
- Authors
- Gu, P.-C., Wang, L., Han, M.-N., Peng, J., Shang, J.-C., Pan, Y.-Q., & Han, W.-L.
- Venue
- Pharmacology
- Publisher
- S. Karger AG
- Published
- 2018-10-25
- Volume
- 103
- Issue
- 1-2
- Pages
- 30-37
- ISSN
- 0031-7012 (ISSN-L)
- 1423-0313
- OpenAlex
- W2898096584
- Cited by
- 22
- References
- 0
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 3
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Phytochemistry and Bioactivity Studies
- Keywords
- mangiferin, pharmacokinetics, alloxan-induced diabetes, diabetes mellitus, oral bioavailability, first-pass metabolism, intravenous administration, oral administration, tissue distribution, diabetic rats, UPLC-MS/MS
- MeSH terms
- Administration, Oral, Alloxan, Animals, Chromatography, Liquid, Diabetes Mellitus, Experimental, Female, Male, Random Allocation, Case-Control Studies, Rats, Sprague-Dawley, Xanthones, Rats, Tandem Mass Spectrometry, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
